Integrated analysis reveals hsa-miR-142 as a representative of a lymphocyte-specific gene expression and Methylation signature

Cancer Informatics

Volumn 11, Issue , 2012, Pages 61-74

  Andreopoulos, Bill ^a   Anastassiou, Dimitris ^a  

^a Columbia University ^*  (United States)

Author keywords

Cancer; Correlation; Gene expression; Integrated analysis; Methylation; MicroRNA

Indexed keywords

FRACTALKINE; MEMBRANE PROTEIN; MICRORNA; MICRORNA 142; UNCLASSIFIED DRUG;

AFF3 GENE; AIF2 GENE; ALDH3A1 GENE; APBB1IP GENE; ARHGAP25 GENE; ARHGAP30 GENE; ARHGAP9 GENE; ARTICLE; BREAST CANCER; BTK GENE; CCL5 GENE; CCR5 GENE; CD2 GENE; CD37 GENE; CD48 GENE; CD53 GENE; CELL ADHESION; CELL FUNCTION; CELL SPECIFICITY; COLON CANCER; CORRELATION COEFFICIENT; CX3CL1 GENE; CXCR3 GENE; CYBB GENE; DNA METHYLATION; DOCK2 GENE; DOK3 GENE; EVI2B GENE; FLJ21438 GENE; FYB GENE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE SIGNATURE; GLIOBLASTOMA; HAVCR2 GENE; HEMATOPOIETIC STEM CELL; HUMAN; IL10RA GENE; ITGB2 GENE; KIDNEY CANCER; LAIR1 GENE; LAPTM5 GENE; LCP2 GENE; LUNG CANCER; LYMPHOCYTE; M GENE; MESENCHYMAL STEM CELL; NCKAP1L GENE; OVARY CANCER; PLEK GENE; PSCD4 GENE; PTPRC GENE; R GENE; RECTUM CANCER; RGR GENE; SASH3 GENE; SLA GENE; TLR2 GENE; TRAF3IP3 GENE; TUMOR GENE; URP2 GENE; UTERUS CANCER;

EID: 84859518571     PISSN: None     EISSN: 11769351     Source Type: Journal    
DOI: 10.4137/CIN.S9037     Document Type: Article

References (47)

1. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259-69.
2. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:2257-61.
3. Bandres E, Agirre X, Bitarte N, et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer. 2009;125:2737-43.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-97.
5. Gabriely G, Yi M, Narayan RS, et al. Human glioma growth is controlled by microRNA-10b. Cancer Res. 2011;71:3563-72.
6. Bredel M, Scholtens DM, Harsh GR, et al. A network model of a cooperative genetic landscape in brain tumors. JAMA. 2009;302:261-75.
7. Kim TM, Huang W, Park R, Park PJ, Johnson MD. A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res.2011;71:3387-99.
8. Li A, Walling J, Ahn S, et al. Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res. 2009;69:2091-9.
9. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of highgrade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer cell. 2006;9:157-73.
10. Spence T, Nguyen J, Bouffet E, Huang A. MicroRNAs in Brain Tumors. MicroRNAs in Cancer Translational Research. Springer Science +Business Media B.V. 2011.
11. Srinivasan S, Patric IR, Somasundaram K. A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One. 2011;6:e17438.
12. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer cell. 2010;17:510-22.
13. Lujambio A, Calin GA, Villanueva A, et al. A microRNA DNA methylation signature for human cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:13556-61.
14. Pavicic W, Perkio E, Kaur S, Peltomaki P. Altered methylation at microRNA- associated CpG islands in hereditary and sporadic carcinomas: a methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA)-based approach. Mol Med. 2011;17:726-35.
15. Zhou X, Ruan J, Wang G, Zhang W. Characterization and identification of microRNA core promoters in four model species. PLoS Comput Biol. 2007;3:e37.
16. Benetti R, Gonzalo S, Jaco I, et al. A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nat Struct Mol Biol. 2008;15:998.
17. Sinkkonen L, Hugenschmidt T, Berninger P, et al. MicroRNAs control de novo DNA methylation through regulation of transcriptional repressors in mouse embryonic stem cells. Nat Struct Mol Biol. 2008;15: 259-67.
18. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857-66.
19. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10:704-14.
20. Buffa FM, Camps C, Winchester L, et al. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res.2011;71: 5635-45.
21. Cancer Genome Atlas Research N, Bell D, Berchuck A, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-15.
22. Dong H, Siu H, Luo L, Fang X, Jin L, Xiong M. Investigation gene and microRNA expression in glioblastoma. BMC Genomics. 2010; 11 Suppl 3:S16.
23. Sun Z, Asmann YW, Kalari KR, et al. Integrated analysis of gene expression, CpG island methylation, and gene copy number in breast cancer cells by deep sequencing. PLoS One. 2011;6:e17490.
24. Xu K, Cui J, Olman V, Yang Q, Puett D, Xu Y. A comparative analysis of gene-expression data of multiple cancer types. PLoS One. 2010;5: e13696.
25. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455:1061-8.
26. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell. 2010;17: 98-110.
27. Enerly E, Steinfeld I, Kleivi K, et al. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One. 2011;6: e16915.
28. Chin L, Hahn WC, Getz G, Meyerson M. Making sense of cancer genomic data. Genes Dev. 2011;25:534-5.
29. Masica DL, Karchin R. Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. Cancer Res. 2011;71:4550-61.
30. Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4:P3.
31. Dietmann S, Lee W, Wong P, Rodchenkov I, Antonov AV. CCancer: a bird's eye view on gene lists reported in cancer-related studies. Nucleic Acids Res.2010;38:W118-23.
32. Lee MS, Hanspers K, Barker CS, Korn AP, McCune JM. Gene expression profiles during human CD4+T cell differentiation. Int Immunol. 2004;16: 1109-24.
33. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007;9:212.
34. Tan W, Zhang W, Strasner A, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 2011;470:548-3.
35. Sciume G, Soriani A, Piccoli M, Frati L, Santoni A, Bernardini G. CX3CR1/ CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-beta1. Neuro Oncol. 2010.
36. Kasashima K, Nakamura Y, Kozu T. Altered expression profiles of microRNAs during TPA-induced differentiation of HL-60 cells. Biochem Biophys Res Commun. 2004;322:403-10.
37. Sun W, Shen W, Yang S, Hu F, Li H, Zhu TH. miR-223 and miR-142 attenuate hematopoietic cell proliferation, and miR-223 positively regulates miR-142 through LMO2 isoforms and CEBP-beta. Cell Res. 2010;20: 1158-69.
38. Yuan W, Sun W, Yang S, et al. Downregulation of microRNA-142 by protooncogene LMO2 and its co-factors. Leukemia. 2008;22:1067-71.
39. Zhao S, Wang Y, Liang Y, et al. MicroRNA-126 regulates DNA methylation in CD4+T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum. 2011;63:1376-86.
40. Segal E, Friedman N, Koller D, Regev A. A module map showing conditional activity of expression modules in cancer. Nat Genet. 2004;36:1090-8.
41. Liu WB, Cui ZH, Ao L, et al. Aberrant methylation accounts for cell adhesion-related gene silencing during 3-methylcholanthrene and diethylnitrosamine induced multistep rat lung carcinogenesis associated with overexpression of DNA methyltransferases 1 and 3a. Toxicol Appl Pharmacol. 2011;251:70-8.
42. McCabe MT, Brandes JC, Vertino PM. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res. 2009;15: 3927-7.
43. Veeck J, Esteller M. Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia. 2010;15:5-17.
44. Kanwal R, Gupta S. Epigenetics and cancer. J Appl Physiol. 2010;109: 598-605.
45. Van Emburgh BO, Robertson KD. Modulation of Dnmt3b function in vitro by interactions with Dnmt3L, Dnmt3a and Dnmt3b splice variants. Nucleic Acids Res. 2011;39:4984-5002.
46. Wienholz BL, Kareta MS, Moarefi AH, Gordon CA, Ginno PA, Chedin F. DNMT3L modulates significant and distinct flanking sequence preference for DNA methylation by DNMT3A and DNMT3B in vivo. PLoS Genet. 2010:6.
47. Chedin F, Lieber MR, Hsieh CL. The DNA methyltransferase-like protein DNMT3L stimulates de novo methylation by Dnmt3a. Proceedings of the National Academy of Sciences of the United States of America. 2002;99: 16916-21.